Sarepta Therapeutics (SRPT) Competitors

Sarepta Therapeutics logo
$15.13 -0.94 (-5.85%)
Closing price 04:00 PM Eastern
Extended Trading
$15.23 +0.10 (+0.69%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SRPT vs. CTMX, EDIT, PRAX, CYTK, and ABVX

Should you buy Sarepta Therapeutics stock or one of its competitors? Sarepta Therapeutics's main competitors and comparable companies include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), and Abivax (ABVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

CytomX Therapeutics currently has a consensus price target of $12.10, suggesting a potential upside of 493.14%. Sarepta Therapeutics has a consensus price target of $23.67, suggesting a potential upside of 47.27%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Sarepta Therapeutics
6 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.00

CytomX Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

In the previous week, Sarepta Therapeutics had 3 more articles in the media than CytomX Therapeutics. MarketBeat recorded 9 mentions for Sarepta Therapeutics and 6 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.65 beat Sarepta Therapeutics' score of 0.58 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CytomX Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Sarepta Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$76.20M5.84-$17.37M-$0.50N/A
Sarepta Therapeutics$2.20B0.78-$713.41M-$1.37N/A

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sarepta Therapeutics has a net margin of -5.86% compared to CytomX Therapeutics' net margin of -608.98%. Sarepta Therapeutics' return on equity of -0.20% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CytomX Therapeutics-608.98% -33.97% -27.19%
Sarepta Therapeutics -5.86%-0.20%-0.09%

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Sarepta Therapeutics (NASDAQ:SRPT) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Sarepta Therapeutics currently has a consensus target price of $23.67, indicating a potential upside of 47.27%. Editas Medicine has a consensus target price of $5.83, indicating a potential upside of 168.82%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics
6 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.00
Editas Medicine
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Sarepta Therapeutics has a net margin of -5.86% compared to Editas Medicine's net margin of -144.95%. Sarepta Therapeutics' return on equity of -0.20% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Sarepta Therapeutics-5.86% -0.20% -0.09%
Editas Medicine -144.95%-130.43%-36.45%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sarepta Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Editas Medicine has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$2.20B0.78-$713.41M-$1.37N/A
Editas Medicine$40.52M8.27-$160.06M-$0.62N/A

In the previous week, Editas Medicine had 12 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 21 mentions for Editas Medicine and 9 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.58 beat Editas Medicine's score of 0.20 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sarepta Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Editas Medicine
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Editas Medicine beats Sarepta Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Praxis Precision Medicines?

Sarepta Therapeutics (NASDAQ:SRPT) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Sarepta Therapeutics currently has a consensus target price of $23.67, indicating a potential upside of 47.27%. Praxis Precision Medicines has a consensus target price of $631.68, indicating a potential upside of 92.51%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics
6 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.00
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.91

Praxis Precision Medicines has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -5.86%. Sarepta Therapeutics' return on equity of -0.20% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Sarepta Therapeutics-5.86% -0.20% -0.09%
Praxis Precision Medicines N/A -29.41%-28.19%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 24 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 33 mentions for Praxis Precision Medicines and 9 mentions for Sarepta Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.63 beat Sarepta Therapeutics' score of 0.58 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sarepta Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Praxis Precision Medicines
7 Very Positive mention(s)
8 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Sarepta Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market.

Praxis Precision Medicines has lower revenue, but higher earnings than Sarepta Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$2.20B0.78-$713.41M-$1.37N/A
Praxis Precision MedicinesN/AN/A-$303.27M-$12.80N/A

Summary

Praxis Precision Medicines beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Cytokinetics had 2 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 11 mentions for Cytokinetics and 9 mentions for Sarepta Therapeutics. Cytokinetics' average media sentiment score of 0.81 beat Sarepta Therapeutics' score of 0.58 indicating that Cytokinetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytokinetics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sarepta Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

86.7% of Sarepta Therapeutics shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cytokinetics presently has a consensus price target of $106.67, suggesting a potential upside of 90.04%. Sarepta Therapeutics has a consensus price target of $23.67, suggesting a potential upside of 47.27%. Given Cytokinetics' stronger consensus rating and higher probable upside, research analysts clearly believe Cytokinetics is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86
Sarepta Therapeutics
6 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.00

Sarepta Therapeutics has higher revenue and earnings than Cytokinetics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A
Sarepta Therapeutics$2.20B0.78-$713.41M-$1.37N/A

Cytokinetics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Sarepta Therapeutics has a net margin of -5.86% compared to Cytokinetics' net margin of -686.63%. Cytokinetics' return on equity of 0.00% beat Sarepta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytokinetics-686.63% N/A -48.26%
Sarepta Therapeutics -5.86%-0.20%-0.09%

Summary

Cytokinetics beats Sarepta Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Sarepta Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Sarepta Therapeutics and 5 mentions for Abivax. Abivax's average media sentiment score of 1.13 beat Sarepta Therapeutics' score of 0.58 indicating that Abivax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sarepta Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abivax has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -5.86%. Sarepta Therapeutics' return on equity of -0.20% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A -91.69% -71.96%
Sarepta Therapeutics -5.86%-0.20%-0.09%

Abivax currently has a consensus price target of $155.00, suggesting a potential upside of 76.98%. Sarepta Therapeutics has a consensus price target of $23.67, suggesting a potential upside of 47.27%. Given Abivax's stronger consensus rating and higher probable upside, equities analysts clearly believe Abivax is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
Sarepta Therapeutics
6 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.00

47.9% of Abivax shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Abivax has higher earnings, but lower revenue than Sarepta Therapeutics. Abivax is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$380.27M-$6.06N/A
Sarepta Therapeutics$2.20B0.78-$713.41M-$1.37N/A

Abivax has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Summary

Abivax and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRPT vs. The Competition

MetricSarepta TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.72B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-11.0426.5532.9127.39
Price / Sales0.7416.028.595.74
Price / CashN/A26.3721.9322.50
Price / Book1.064.074.403.70
Net Income-$713.41M-$22.86M$3.52B$392.17M
7 Day Performance-12.24%-7.26%-5.34%-4.53%
1 Month Performance-11.52%-4.96%-3.61%-5.86%
1 Year Performance-19.56%-2.87%0.01%-7.78%

Sarepta Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRPT
Sarepta Therapeutics
3.5203 of 5 stars
$15.13
-5.8%
$23.67
+56.4%
-14.6%$1.72B$2.20BN/A835
CTMX
CytomX Therapeutics
2.0622 of 5 stars
$1.98
-9.6%
$12.00
+506.1%
-47.4%$512.06M$76.20MN/A69
EDIT
Editas Medicine
2.3197 of 5 stars
$2.75
+7.0%
$5.83
+112.1%
-16.5%$417.74M$40.52MN/A87
PRAX
Praxis Precision Medicines
2.918 of 5 stars
$332.97
+19.9%
$630.42
+89.3%
+76.0%$7.95B$8.55MN/A168
CYTK
Cytokinetics
3.066 of 5 stars
$55.14
+2.7%
$106.67
+93.4%
-15.5%$7.91B$88.04MN/A673

Related Companies and Tools


This page (NASDAQ:SRPT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners